
Zevor-cel (CT053)3
Conventional
CT053 is a BCMA-specific CAR T product candidate, consists of autologous T cells genetically modified with a CAR incorporating a fully human anti-BCMA single chain fragment variant with high binding affinity that specifically recognizes BCMA.

Investigator-Initiated Trial in China
Phase I/II Clinical Trial for MM in China (LUMMICAR STUDY 1)

for relapsed and/or refractory multiple myeloma (R/R MM)

for relapsed and/or refractory multiple myeloma (R/R MM)

Breakthrough Therapy Designation, NMPA
for relapsed and/or refractory multiple myeloma (R/R MM)

for multiple myeloma (MM)

Orphan Drug designation, EMA
for multiple myeloma (MM)
Conventional
CT041
Conventional
CT041 is an autologous CAR T product candidate that targets Claudin18.2 (“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.

Investigator-initiated trials
Phase Ib clinical trial for advanced GC/GEJ and PC
Confirmatory Phase II clinical trial for advanced GC/GEJ

for advanced gastric /gastroesophageal junction adenocarcinoma (GC/GEJ) with Claudin18.2-positive tumor

for advanced gastric cancer

for gastric /gastroesophageal junction cancer (GC/GEJ)

Orphan Drug designation, EMA
for advanced gastric cancer
Conventional
CT011
Conventional
CT011 is an autologous CAR T product candidate that targets glypican-3 (GPC3), which is highly expressed in HCC and is suggested to be a prognostic marker for the disease.

Investigator-Initiated Trial for HCC
Phase I Clinical Trial for HCC
Conventional
sFv-ε
sFv-ε
THANK-uCAR®
CycloCAR®
Undisclosed
CycloCAR®
THANK-uCAR®
Undisclosed

AB011
AB011 is a humanized monoclonal antibody product candidate that targets Claudin18.2(“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.

Phase I Clinical Trial for CLDN18.2 Positive Advanced GC/GEJ and PC (AB011-ST-01)
R/R MM: relapsed / refractory multiple myeloma; GC: gastric cancer; GEJ: gastroesophageal junction cancer; PC: pancreatic cancer; HCC: hepatocellular carcinoma; AML: acute myeloid leukemia
1 All product candidates are self-developed with global rights
2 Phase II trials of some indications are pivotal studies
3 Core Product Candidate. Commercial rights in mainland China have been granted to Huadong Medicine (SZ: 000963). Rights in the South Korean market have been licensed out to HK Inno.N (KOSDAQ: 195940)